| dc.creator | Vilos C. | |
| dc.creator | Constandil L. | |
| dc.creator | Rodas P.I. | |
| dc.creator | Cantin M. | |
| dc.creator | Zepeda K. | |
| dc.creator | Herrera N. | |
| dc.creator | Velasquez L.A. | |
| dc.date.accessioned | 2020-09-02T22:30:26Z | |
| dc.date.accessioned | 2022-11-08T20:27:13Z | |
| dc.date.available | 2020-09-02T22:30:26Z | |
| dc.date.available | 2022-11-08T20:27:13Z | |
| dc.date.created | 2020-09-02T22:30:26Z | |
| dc.date.issued | 2014 | |
| dc.identifier | 8, , 651-666 | |
| dc.identifier | 11778881 | |
| dc.identifier | https://hdl.handle.net/20.500.12728/6585 | |
| dc.identifier.uri | https://repositorioslatinoamericanos.uchile.cl/handle/2250/5146351 | |
| dc.language | en | |
| dc.publisher | Dove Medical Press Ltd. | |
| dc.subject | Blood parameters | |
| dc.subject | Drug delivery | |
| dc.subject | Microparticles | |
| dc.subject | Rat infection model | |
| dc.subject | Salmonella typhimurium | |
| dc.subject | ceftiofur | |
| dc.subject | copolymer | |
| dc.subject | poly(3 hydroxybutyrate co 3 hydroxyvalerate) | |
| dc.subject | unclassified drug | |
| dc.subject | ceftiofur | |
| dc.subject | cephalosporin derivative | |
| dc.subject | poly(3-hydroxybutyrate)-co-(3-hydroxyvalerate) | |
| dc.subject | polyester | |
| dc.subject | animal experiment | |
| dc.subject | animal model | |
| dc.subject | area under the curve | |
| dc.subject | article | |
| dc.subject | controlled study | |
| dc.subject | drug efficacy | |
| dc.subject | drug half life | |
| dc.subject | drug safety | |
| dc.subject | drug synthesis | |
| dc.subject | encapsulation | |
| dc.subject | male | |
| dc.subject | maximum plasma concentration | |
| dc.subject | minimum inhibitory concentration | |
| dc.subject | nonhuman | |
| dc.subject | rat | |
| dc.subject | Salmonella typhimurium | |
| dc.subject | salmonellosis | |
| dc.subject | sustained drug release | |
| dc.subject | time to maximum plasma concentration | |
| dc.subject | toxicity testing | |
| dc.subject | animal | |
| dc.subject | disease model | |
| dc.subject | dose response | |
| dc.subject | drug effects | |
| dc.subject | erythrocyte | |
| dc.subject | intramuscular drug administration | |
| dc.subject | microbial sensitivity test | |
| dc.subject | microbiology | |
| dc.subject | Salmonella enterica serovar Typhimurium | |
| dc.subject | Salmonella Infections | |
| dc.subject | Sprague Dawley rat | |
| dc.subject | structure activity relation | |
| dc.subject | Animals | |
| dc.subject | Cephalosporins | |
| dc.subject | Disease Models, Animal | |
| dc.subject | Dose-Response Relationship, Drug | |
| dc.subject | Erythrocytes | |
| dc.subject | Injections, Intramuscular | |
| dc.subject | Male | |
| dc.subject | Microbial Sensitivity Tests | |
| dc.subject | Polyesters | |
| dc.subject | Rats | |
| dc.subject | Rats, Sprague-Dawley | |
| dc.subject | Salmonella Infections | |
| dc.subject | Salmonella typhimurium | |
| dc.subject | Structure-Activity Relationship | |
| dc.title | Evaluation of ceftiofur-PHBV microparticles in rats | |
| dc.type | Article | |